Uptake of mandated pregnancy warnings in the Australian alcoholic ready-to-drink beverage market.


Journal

Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440

Informations de publication

Date de publication:
Jan 2024
Historique:
revised: 12 09 2023
received: 22 06 2023
accepted: 18 09 2023
medline: 31 1 2024
pubmed: 11 10 2023
entrez: 11 10 2023
Statut: ppublish

Résumé

A mandatory pregnancy warning was introduced in Australia 2020 to advise the public of the potential harms of prenatal alcohol exposure. Due to industry pressure, a 3-year implementation period was granted. The aim of this study was to analyse the extent to which the mandatory warning had been applied to ready-to-drink (RTD) alcohol product labels almost 2 years into the implementation period. The sample included 491 RTD products sold in three alcohol stores in Sydney, Australia in March-May 2022. Identified warnings were categorised as a mandated warning, a DrinkWise warning (an industry-developed option) or 'Other' warning. Analyses were conducted overall and by RTD type. Almost all (94%) of the sampled RTD products had some form of pregnancy warning, but only 36% displayed the mandatory version. Of the non-mandatory warnings, 74% were DrinkWise warnings (42% of total sample) and 27% were 'Other' warnings (15% of total sample). There was no apparent relationship between alcohol content and likelihood of displaying a mandatory warning. Two years into the three-year implementation period for the mandatory pregnancy warning, only around one-third of the assessed RTD products exhibited compliance. Uptake of the mandatory pregnancy warning appears to be slow. Continued monitoring will be required to determine whether the alcohol industry meets its obligations within and beyond the implementation period.

Identifiants

pubmed: 37819809
doi: 10.1111/dar.13758
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-169

Subventions

Organisme : National Health and Medical Research Council
ID : GNT1149987

Informations de copyright

© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.

Références

Int J Environ Res Public Health. 2021 Mar 26;18(7):
pubmed: 33810338
PLoS One. 2022 Dec 7;17(12):e0276189
pubmed: 36476743
Pediatrics. 2005 Jan;115(1):39-47
pubmed: 15629980
JAMA. 2018 Feb 6;319(5):474-482
pubmed: 29411031
Lancet Public Health. 2023 Jan;8(1):e28-e35
pubmed: 36603908
Drug Alcohol Rev. 2024 Jan;43(1):165-169
pubmed: 37819809
Health Promot Int. 2023 Jun 1;38(3):
pubmed: 35462394
JMIR Mhealth Uhealth. 2014 Aug 21;2(3):e37
pubmed: 25147135

Auteurs

Bella Sträuli (B)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Tazman Davies (T)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Stephen Jan (S)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Leon Booth (L)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Nadia Laznik (N)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Fraser Taylor (F)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Simone Pettigrew (S)

The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH